Notes

The EPM1734 paper had an actual open of 3.73 on September 10 at 13:30, with an ADR of 11124, a stop at 3.61876, and a target of 3.89686, and was set to exit before September 15. There was no order placed. The base fees were 5 basis points with a 10 basis point slip and 25 basis point stress, and the cost was calculated in cash as 3.735596865 and 3.741194663 with a stress risk ratio of 1.080227. The paper was checked at 1930 and found to be authoritative, with 1734 and 1928 being checked and observed as 22831, but no new test or retune was done. Monitor 167 was resolved and 168 was retained for exit review at 16:30. The LOVE 192 was also resolved and will be reviewed at 16:30, covering the conditional guide bridge and public content for SRRK, M-MCFT, and CAL403. The actual PPI for August was 0.4 month-over-month and 5.4 year-over-year, with a July revision from 0 to 0.1 now verified as of 22807 and 29, which was not a forecast surprise. Five jobs were active, with payload footers checked for 67, 75, 126, 132, and 172. A news Value Error persists for 172 IPHA, with no fresh claim. Outputs for 132 and 75 were completed at 13:15, and the next output for 126 is due at 15:15 before 16:30, and for 172 at 16:30:53 after the run starts. There was no new tradable off-run signal, and existing collectors will cover issuer changes, so paper bars need to be fetched manually at the monitor. The scope stops at existing trading notes, with no new universe optimization. The LOVE call registration and SRRK JS shell were not full replays, so unknown elements will be preserved.

The plan started at 13:50:55 UTC and will take 33 minutes to complete, including a final 5-minute journal review, with a hard stop at 45 minutes. The current cash level is still suitable, and expectations of attractive news should be set aside. The plan is to review the actual opening on September 10 and any changes to issuers since 12:39, rather than searching for a new strategy. The plan includes a series of questions: Is the EPM paper input valid? Is the SIP actual open valid, considering timestamp and session, adjustment, and corporate actions? Is the catalyst still intact, considering the issuer's earliest release and potential early news contamination? Is there new information, such as a cash or guide bridge, with considerations for refund treatment and organic margin? What is the reaction to this information, including current consolidated print and gap versus frozen sample? Are there other morning gaps, including primary macro considerations like August PPI and revisions, and cost transmission? Are there issuer-specific considerations, such as M/MCFT/CAL and SRRK public replay? What are the binding constraints, including frozen edge, train and holdout uncertainty, and costs and execution time? Is the book feasible, considering fund and equity levels, and is there no shortfall-based sizing? No orders will be placed, and only CIO proposals will be considered. Relevant lessons from previous experiences include payload freshness, refund bridge, and no pressure exception, specifically lessons 645-647.

The Catalyst Research fund has a size of 0 and a UTC time of 2026-09-10T13:15:48.904719+00:00. The fund manager reviewed SEC filings for HITI on 2026-08-31 and BFRI on 2026-08-13. On September 1, 2026, Dave & Buster's Entertainment, Inc. announced it will report its second quarter results. The fund manager also reviewed static data for several companies, including TSM, DATA.L, ET.TO, GIS, and NKE, with release dates of September 10, 14, 15, 23, and October 2, respectively. New reviews were added for CAN on September 8, PLAY on September 15, ABVX on September 21, EGTX.ST on September 25, and 4431.T on September 14. The fund manager made decisions based on organic cash and clinical evidence, and rejected a proposal for PLAY with a 13.15% train error and a 6.88% confidence interval. An early decision is possible for EGTX, but it is not bounded by a stop. The fund manager also reviewed 48 articles about EGTX, with the latest one found at https://mfn.se/a/egetis-therapeutics/emcitate-r-tiratricol-presentations-at-eta-and-espe-congresses-in-september-2026. The fund manager will record and validate new labels, PRV, and cash for EGTX, and reverify in case of adverse or delayed events.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 10, 2026, at 13:15:47 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed the SFIX 8-K filing from July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 10, 2026. The fund also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The fund will review new results on September 9 at 12:30 UTC, LOVE results on September 10 at 12:30 UTC, and SFIX results on September 24 at 12:30 UTC. The GRAL meeting on September 23 is not for approval. The fund has a strong cash position, which needs to be recorded and validated, while weak or early positions need to be verified. No automatic orders were made.

A news scan found the headline 'PRE91012 handoff: cash; LOVE refund bridge; monitors192/193'. On September 10, a trading run occurred from 12:31 to approximately 12:39 UTC, finishing at 12:36. There were no proposals made during this time. The cash balance was $49.14 in the fund and $850.99 in the account. Lessons 624-626 and analyses 2231-35 were applied. The LOVE, EPM, and TLX positions remained unchanged. A simulation and indicators were run, but no new tests or return observations were made. The Kelly criterion was approved with a value of 0. Resolutions 22 and 183 were made, with successors 192 on September 10 at 13:50 and 193 on September 11 at 12:45. Monitor 192 checked the LOVE call, guide comparability, and current SIP reaction, as well as the actual August PPI and revisions. Monitor 193 checked the TLX date and CPI, and researched the ZUMZ September 10 AMC call. Both monitors were for research purposes only. The EPM position was unchanged, and the ORCL, CPRT, ADBE, and KR positions were also unchanged. A refund of $21 million was received from LOVE, and the sales guide was updated from $720 million to $700 million. The nominal EBITDA was updated from $40.5 million to $33.5 million. The primary release and 10Q URLs were updated. All five active jobs were checked, and no new jobs were needed. The workspace included research.py, more.py, and various JSON files. Decision numbers were persisted, and verbal elapsed estimates were corrected to the tool clock.

A trading run started at 12:31 UTC and is planned to last 35 minutes, including the last 5 minutes for journaling and reporting, with a hard stop at 45 minutes. Previously, there were no existing rules to support deployment, and the belief that attractive news must create an entry was set aside. The resolution is based on issuer changes since 08 UTC, plus the eligibility of frozen evidence, not new universe optimization. The question tree is as follows: 1. Was there an early outcome for TLX? 1.1. Was it related to the FDA or the issuer's original information? 1.1.1. Was the Pixclara decision related to the unrelated Ga68 news? 1.1.2. Was there an overlap between Zircaix and the full pipeline? 1.2. What were the economic consequences? 1.2.1. Were there changes to the label or manufacturing? 1.2.2. Were there changes to cash or collaborations? 2. Did the morning earnings change the facts? 2.1. Did LOVE's actual results differ from the prior guide? 2.1.1. Were there changes to organic sales or margins? 2.1.2. Were there changes to refunds, cash, or inventory? 2.2. Were there other original releases? 2.2.1. Were there releases from M, MCFT, or CAL? 2.2.2. What was the timing of the releases versus the call? 3. Is there a feasible edge? 3.1. Are there frozen tests? 3.1.1. What were the training, holdout, and cost? 3.1.2. What were the sample and censoring? 3.2. Is the implementation feasible? 3.2.1. Is it a fresh session with whole shares? 3.2.2. What is the net risk-reward and gap risk? 4. Are there outer constraints? 4.1. What is the actual timing of the PPI and CPI? 4.1.1. What are the revisions and components? 4.1.2. Is there an issuer cost pass-through? 4.2. What are the incentives and downstream? 4.2.1. Are there management-adjusted metrics versus cash? 4.2.2. Can a monthly shortfall alter the risk? The fund started flat with $49.14 in cash, with the goal of achieving repeatable pre-event gains, and the binding constraint is an independent costed event edge. There are no orders, and the CIO receives proposals only. Note: PPI stands for Producer Price Index, CPI stands for Consumer Price Index, and FDA stands for Food and Drug Administration, which is a US government agency that regulates food, drugs, and medical devices.

The fund is called Catalyst Research and it is for research purposes only. The size of the fund is 0 and the time is 12:30:57 on September 10, 2026. There are several news updates from various companies, including Telix Pharma on September 10, 2026, Mission Produce on September 8, 2026, ABM on September 8, 2026, Roivant on September 8, 2026, and Evolution Petroleum on September 8, 2026. There are also several financial reports, including an 8-K report from UNFI on September 8, 2026, a 10-K report from DRI on July 24, 2026, a 10-Q report from PPIH on September 9, 2026, a 10-Q report from MRK on August 7, 2026, and an 8-K report from WLTH on September 9, 2026. Additionally, there is a 6-K report from IPHA on September 10, 2026. The HTTP status for KGF is 200 with a hash of dda88bf6ef8ad805, for ASKUL is 200 with a hash of e6f0d85c03a37ce6, and for SOBI is 200 with a hash of cec04eec9001d2f4. However, there was an error with IPHAnews due to a ValueError. The research is ongoing and no orders have been placed. The monitors for 165, 168, 167, 137, and 22 will be preserved. The sources and dates are recorded in the job script and journal. A review of the originals and validation is required for strong and new information, while weak or absent information requires cash and reverification. There is a conditional receipt for Sobi and a Q1 2028 condition, and IPHA has a deadline of September 17.

The fund manager of the Catalyst fund is researching IONS, MIRM, and GIS. The fund size is 0 and the current time is 2026-09-10T11:15:51.796754+00:00. The manager has found the following SEC filings: IONS on 2026-09-04, MIRM on 2026-09-08, GIS on 2026-07-01, and EAT on 2026-08-12. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on 2026-09-09. GIS had a conference on September 8, which has already passed. The manager notes that STATIC, or a static event, is scheduled for September 23, with earnings and a Q&A session at 13UTC. The manager will review GIS's organic cash and guide, and will record and validate if it is stronger, or reverify if it is weaker or absent. The baseline for GIS's FY27 EPS is 3.00-3.20, with organic growth of -1.5 to +0.5% and savings of 750m. The manager has also found information on EAT, including an investor day on September 17 and an earnings call on October 28. The manager will review EAT's organic cash and guide, and will record and validate if it is stronger, or reverify if it is weaker or absent. The manager notes that the investor day odds are untested and that static dates are not armed.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 10, 2026, at 09:01:17 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, available at https://www.sec.gov/Archives/edgar/data/1766502/000162828026061018/chwy-20260802.htm, ASO's 10-Q filing on September 9, 2026, available at https://www.sec.gov/Archives/edgar/data/1817358/000181735826000149/aso-20260801.htm, LOVE's 8-K filing on June 15, 2026, available at https://www.sec.gov/Archives/edgar/data/1701758/000121390026068869/ea0294793-8k_lovesac.htm, and SFIX's 8-K filing on July 28, 2026, available at https://www.sec.gov/Archives/edgar/data/1576942/000162828026050133/sfix-20260722.htm. The manager also reviewed the following RSS feeds: SAIL's announcement on September 9, 2026, at 07:00:50 -0400, available at https://investor.sailpoint.com/news-releases/news-release-details/sailpoint-announces-fiscal-second-quarter-2027-results, KFY's announcement on September 9, 2026, at 06:45:00 -0400, available at https://ir.kornferry.com/news-events/press-releases/detail/733/korn-ferry-announces-first-quarter-fiscal-2027-results-of-operations, and LOVE's announcement on August 27, 2026, at 07:00:00 -0400, available at https://investor.lovesac.com/news-events/press-releases/detail/166/the-lovesac-company-announces-second-quarter-conference. Additionally, the manager reviewed an FDA update, which included a meeting on September 23, 2026, available at https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting. The manager noted that SEC filings may lag behind news and reviewed the following schedules: new morning results on September 9 at 12:30, LOVE's results on September 10 at 12:30, and SFIX's results on September 24 at 12:30, after the AMC on September 23. The manager also noted that GRAL's panel on September 23 is not an approval. The manager emphasized the importance of strong cash positions, which should be recorded and validated, while weak or early positions should be cashed and reverified. No automatic orders were placed.

The fund is called Catalyst Research and it has no size. The current time is 2026-09-10T09:01:17.236761+00:00 UTC. There are some updates about the stocks SRRK, SCHL, and PRAX. SRRK is Scholar Rock, which received FDA Fast Track Designation on September 2, 2026. On August 27, 2026, Scholar Rock announced it will present at upcoming investor conferences. On August 21, 2026, Scholar Rock provided an update on its apitegromab regulatory progress. SCHL is Scholastic Corporation, which announced the date for its first quarter fiscal 2027 on September 3, 2026. PRAX is Praxis Precision Medicines, Inc., which announced inducement grants on September 3, 2026. There is also a SEC filing for SRRK on August 6, 2026. The fund will review SRRK on September 9, 12UTC, September 10, 13:20UTC, and September 29, 12:30UTC before the PDUFA on September 30. SCHL will have a release on September 24, 16ET, and will be reviewed on September 25, 12:30UTC. PRAX will replace its previous update on September 27 with a new one on December 27. The fund uses a system where favorable data leads to recording and independent validation, while adverse, delayed, or absent data leads to cash or re-verification. There are no automatic entries and static reminders are not exact execution times. The fund has 3 SRRK, 1 SCHL, and 1 PRAX, and 1 SEC filing, but this is not an exhaustive list.

The Catalyst research fund has a size of 0 as of 2026-09-10T08:15:59.448257+00:00 UTC. Recent news includes: TLX on Thu, 10 Sep 2026, with an update on reliable access and availability of Ga-68 radiopharmaceuticals at https://telixpharma.com/news-views/reliable-access-and-availability-of-ga-68-radiopharmaceuticals/. AVO announced fiscal 2026 third-quarter financial results on Tue, 08 Sep 2026, at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial. ABM reported fiscal third-quarter 2026 results on Tue, 08 Sep 2026, at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results. ROIV announced positive results from the Phocus study of mosliciguat on Tue, 08 Sep 2026, at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. Other updates include UNFI's 8-K filing on 2026-09-08, DRI's 10-K filing on 2026-07-24, PPIH's 10-Q filing on 2026-09-09, MRK's 10-Q filing on 2026-08-07, and WLTH's 8-K filing on 2026-09-09. EPM scheduled fiscal Q4 and full-year 2026 results on Tue, 08 Sep 2026, at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-schedules-fiscal-q4-and-full-year-2026. IPHA filed a 6-K on 2026-09-02. HTTP requests returned the following hashes: KGF with hash dda88bf6ef8ad805, ASKUL with hash e6f0d85c03a37ce6, IPHAnews with hash 63c1ed7a93468887, and SOBI with hash cec04eec9001d2f4. Research only, with a note to read originals and validate strong or new information, and to cash and reverify weak or absent information. IPHA has a deadline of Sep 17, and Sobi has a conditional receipt and Q1-2028 deadline. Monitors 165, 168, 167, and 137, and 22 are preserved. Sources and dates are available in the job script and journal. No orders have been placed.

At 12:30 UTC on September 10, the fund manager made the following decisions: retain $49.14 in cash and do not place any new orders or stops. The manager did not own any overdue monitors and left other funds untouched. A new set of instructions, numbered 183, replaced the old set, numbered 137, at the same time, with a focus on LOVE, MCFT, CAL, M, and PPI. The manager preserved positions in TLX, EPM, and DRI, but did not make any live catch-up trades. The manager reviewed the actual LOVE report, which showed an EBITDA of -4 to +2 million, including a 3.6 million refund. The manager also reviewed MCFT and CAL's organic demand, margins, inventory, and cash, as well as PPI's actual headline, core, and revisions. The manager noted that CPI data would be released the next day at 08:30 ET. After resolving the new set of instructions, the manager armed trades for ZUMZ, ORCL, CPRT, ADBE, and KR. The manager also reviewed TLX's new cash position and noted that the approval date for this information was September 11, but this was not guaranteed. The manager used a new generic momentum model, which showed a train value of -25.273% and a holdout value of +11.035% with a confidence interval of [-2.092, 3.590]%. The manager adopted a Kelly criterion of 0 and noted that the technical RR was 0.9054. The manager also noted that improving label, cash, and tape changes were being watched, but that money required independent notice-aware costs, stressed actual-window edge, positive conservative expectancy, net RR >= 1.5, fresh quotes, whole-share feasibility, and <= 49.14 book, 212.7475 position, and 8.5099 equity risk. The manager documented the exit before the first news release. Prior LOVE, DRI, and EPM trades remained frozen. The manager collected payloads from collectors 67, 75, 126, 132, and 172, and noted that 126 was complete at 07:01, but 172 was not yet executed at 08:11. The manager also noted that static references 165 and 137 were stale, but current references 176 and 183 were authoritative. The manager did not need to create a new job due to a flat book. The manager noted several gaps in the data, including unverified headlines from TSM and DOL, and missing coverage of the ECB and small issuers. The manager archived parts 1886 and 29, and noted that all research threads were within allowances. The finish phase began at approximately 08:10, and the unused budget remained unspent. A news scan found the headline 'TSM 53%'. The manager reviewed the actual paper entry for EPM 167 and noted that the exit for EPM 168 was scheduled for September 14. The manager also reviewed the paper entry for DRI 179, which was scheduled for September 17.

A news scan found the headline 'TLX08 reproducible archive manifest'. The source code was adjusted using SIP daily TLX 454 and SPY 674 bars, with no next page. The full raw data consists of 1128 bars. The audit.py code uses exact vectorbt code, and the results are stored in results.json and cli.json. The observations are listed as 21498, 21499, 21500, 21501, 21502, 21503, 21504, 21506, 21508, 21510, 21512, 21513, 21515, 21517, 21519, 21521, 21523, 21525, 21526, 21528, 21530, 21532, 21534, 21536, 21538, 21540, 21541, 21543, and 21545. These observations concatenate note fields in listed order, base64 decode, gzip decompress, and JSON parse filename to text. The raw SHA256 is 8798f8d1b61646628515975304044d88fb3acf491b95d06cc963e64fc9791d2b. Writing files and then running python3 audit.py reproduces base outputs. The results.json file additionally includes illustrative 1 ADR and 1.5 ADR cost geometry, where stop equals current price minus ADR, target equals current price plus 1.5 ADR, and net equals exit multiplied by 1 minus 0.003, divided by entry multiplied by 1 plus 0.003, minus 1. All 12 cells were recorded from 21462 to 73, and the bar ended on September 9. The CLI command is in 2167. There are no current quotes or exact 15-minute execution, or FDA event cohort, and the diagnostic is not live edge. The source is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=TLX,SPY&timeframe=1Day&feed=sip&adjustment=all, with fundamental raw inputs 21447 and PDF source. The files are also in /tmp/codex-run-VXmfBe, but persistence is not assumed.

A fund manager for the Catalyst fund, which trades the LOVE symbol, confirmed on September 10 that the company's before-open results and a review of the paper rule were completed. This review was scheduled for 08:30 ET and was not the first news about it. The issuer had previously announced on August 27 that the results would be released on September 10. The review compared the company's second-quarter earnings before interest, taxes, depreciation, and amortization, or EBITDA, which is a measure of a company's overall financial performance, to a guide of -4 to +2 million, including a 3.6 million expected refund. It also looked at organic demand, margin, inventory, cash, and tariff refund classification. On September 9, the fund manager recorded a frozen paper from 09:30 to 15:45 and set a stop-target outcome using a 15-minute SIP, which is a type of trading data, and not IEX ADR, which is a type of stock listing. The previous stress test showed a -0.3685% and -2.3414% result, and the confidence interval, which is a measure of the reliability of the results, crossed zero. If the results were strong, with good cash and new paper, the fund manager would record it without rechecking, but if the results were weak or early, the fund manager would recheck the cash and verify the issuer's information. No order or automatic entry was made. The fund manager is now expanding the same 12:30 UTC review to include MCFT, CAL, and M, and PPI, with full URLs for the calendar years 2162 and 2163, while preserving all frozen LOVE rule metrics and the semantics of the call not being the first news. No result will be claimed before the actual release. There will be zero entry. The existing TLX22 and EPM167 will remain.

The trading plan for September 10 starts at 08:01:20 UTC and will last for 40 minutes, with 5 minutes to finish and a hard stop at 45 minutes. The plan starts with the least predictable events. There are several events to consider, including early regulatory news, such as TLX approval or delay, and the release of original notices from issuers like LOVE, ORCL, ADBE, CPRT, and KR. The plan also considers macroeconomic clustering, including BLS dates and times, ECB, claims, and EIA. The next step is to assess the edge, including whether whole shares can be executed affordably, considering price, spread, and session, as well as stop gaps. The plan also reviews prior event evidence, including train and holdout costs, selection bias, and the operator's own record, including censoring and RARE gap. The outer structure of the plan considers whether event expectations have already been disseminated, media repetition, cash capture, supplier and customer benefits, financing, and macro discount-rate shock. The handoff section of the plan checks for due Catalyst monitors, scope and branches, collectors, timestamps, footer, and errors, as well as change-mind evidence, requiring independent executable edge. Previously, the plan was to likely retain cash given failed tests, set aside and inspect fresh primary changes, and resolve the exact event date and session, not guessed release minute, and discard analyst-target chatter as entry evidence. Applicable lessons are 615-617.

The fund manager of the Catalyst fund is researching IONS, MIRM, and GIS. The fund size is 0 and the current time is 2026-09-10T07:01:12.294974+00:00. The manager has found the following SEC filings: IONS on 2026-09-04, MIRM on 2026-09-08, GIS on 2026-07-01, and EAT on 2026-08-12. On 2026-09-09, Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, which has already passed. The manager will review the replay. On September 23, GIS will release its earnings, and the manager will review them at 13UTC. The manager has set a baseline for GIS's fiscal year 2027, expecting an EPS of $3.00-3.20, organic growth of -1.5 to +0.5%, and savings of $750m. The manager has also noted EAT's investor day on September 17 and earnings call on October 28. The manager will review these events at 16:30UTC. The manager has set rules for trading, including recording and verifying GIS's and EAT's organic cash growth. The manager will not make automatic trades and will reverify news before making any decisions.

The fund manager is retaining 49.14 cash with no orders. A diagnostic check on DRI, which is a type of investment, showed a 4.45405% stress level, with 4 out of 6 parameters, or p, meeting the criteria, and a mean confidence interval of -1.49818 to 2.52709%. The training data from 12 showed a 2.87749% increase. However, this is not a fresh, independent holdout, meaning it's not a new, separate test. Indicators for 2021 and 2022 showed a reverse sign, and a simulation for the second quarter of 2021 showed a general Kelly criterion of 2.20366 times, but it was approved at 0. A technical analysis for 2021 showed a costed risk-reward ratio of 0.96959, with a full share price of 209.42 being greater than the book value. Statistical analysis for 2021 showed 3 losses, with 2 being censored, meaning they were not fully observed. A new monitor was started on September 17 at 13:50 UTC to review the actual paper entry, and then it was armed on September 23 for the paper exit, with no orders. A notice for IPHA on September 10 corrected a previous call from September 17 at 08:00 EDT or 14:00 CEST. The monitor 176 replaces 165 and 174, which were previously resolved. The Q1 2028 runway is still conditional, with no verified receipt of 75 million from Sobi. The current Innate page is valid, and the prior job 172 had an HTTP 200 status, which means it was saved successfully, and was not an error. Job 172 was completed at 04:15, and the next job will start at 08:15 after the 08:00 run. The existing 22 TLX, 137 LOVE, and 167 EPM, and 168 combined were preserved. All 5 collectors were retained, with no extra automation needed before 08:00. The archive 1860 has 118 raw parts, 5536 bars, 61 metric records, and 4 code parts, which were all verified to be exact. The source audit json file contains initial 5 date-string misses, but HTML entity decoding with declared user agent was verified for all 18, and 20546 was authoritative. The remaining 11 training advance notices were not verified, and were not date changes. There was no parameter refit after the paper win. The final phase was from approximately 06:16 to 20:00 UTC, which was inside the planned 43 and hard 45 time limits, with unused time being unspent.

The DARDEN06 audit1832 and backtest2122 had an exact readback of 118 raw parts, 61 measure records, and 4 code parts, which all passed. The raw data consisted of 5536 bars, including 1427 DRI and 1427 SPY daily bars, and 2682 DRI 15-minute bars, with 2340 of those being during regular trading hours. There were also 18 dated events. The raw data's SHA256 hash is 73106cca6111e7ea468d9035cbdf6a5533ff63cb0961faba7040105ec74f324e. The notes of raw observation IDs were concatenated, base64 decoded, gzip decompressed, and JSON parsed into a filename-to-object map, and each JSON file was written. The raw IDs are listed as 20842, 20844, 20846, and so on. The code notes 1849, 1850, 1851, and 1852 had the same base64, gzip, and JSON filename-to-exact-text, with a SHA256 hash of f9a925a2f6153f52c1f32ca719f643a198bc7b6c09913a319c9033bbeab7c027. The instructions are to run python3 audit.py, then python3 risk.py, and fetch.py will requery the vendor only if needed. The output observations 21348, 21349, 21350, and so on, had the same code, with a SHA256 hash of 45c8465ecaa3829bc2c743f7648d977bbb16e824b91f689dea064043f361f3d4. The risk_results.json file is authoritative, with 8 size and shock cells, seeded on 20260910061. The results simulation initially included 6 cells, with 1 clipped duplicate, but not additional independent trials. The numerical data and code are complete, but the local path is not assumed to be persistent. The archived bars were adjusted for SIP, not quotes, and 11 training advance notices are still missing.

A news scan found the headline or data line that appears to be a gzip-base64 encoded string, which is 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.

A news scan found the following information about several companies. The companies CAL, WGO, CTAS, and FDX were reviewed for new information, but did not produce any eligible new data. CAL had already reported on September 9, which was a secondary discovery with no financial claims. WGO's last visible call was on June 25, but no future date was validated. CTAS did not provide proof of a date. FDX's fiscal calendar was recast, which can be found at https://www.sec.gov/Archives/edgar/data/1048911/000104891126000108/fedexrecastexhibit991.htm, and this defeats the assumed lead of September 17. DRI had a positive existing test, number 1376, which merits a new execution audit, number 1832, but not a new independent issuer selection. SFIX was reverified on September 23, and the information can be found at https://investors.stitchfix.com/news-events/press-releases/news-details/2026/Stitch-Fix-Announces-Date-for-Fourth-Quarter-and-Full-Fiscal-Year-2026-Financial-Results-and-Conference-Call/default.aspx. The scope of the review is bounded by US consumer and logistics companies, plus French biotech companies. There is no separate FUND edge.

A news scan found the text: Before 15 minute fetch and inspection, retain 18 dates and 2022-24 train and 2025-June 2026 test from 1376 observations and 16251-74. These holdout daily returns are already known, so the new exit rule is a post-selection execution diagnostic, not independent fresh validation. The fixed T5 open and forced T1 15:45 open, with entry at 09:30, are used for comparison of time only. The strategy uses 1 ADR 20 stop and 1.5 ADR target, with the same plus 1 ADR sell half and move stop entry. ADR uses 20 daily bars before entry. Fractional DRI cannot exit during extended hours, so the sample uses RTH 15 minute opens only, with stop and target observed at grid fill that open plus costs, not OHLC touch at barrier. Overnight gap fills next RTH open, with 15 minute quote history unavailable. Fees are 10 basis points per side, with slip 10 basis points baseline 25 basis points stress. Train-only sensitivity ADR stop is 0.75, 1, and 1.25, and target 1.5 and 2 ADR, and does not choose holdout winner. Reconcile vector backtest long only cash with manual ledger, including entry fees and partial fees. Descriptive indicator groups include prior close greater than SMA 50, 20 day momentum greater than 0, SPY greater than SMA 200, and ATR percent above historical training median, with no signal refit. Monte Carlo simulation uses 50,000 whole event paths with gap stress and quarter Kelly, distinguishing risk fraction from capital fraction. Zero if CI crosses zero, unaffordable, or validation gaps. Clock correction, previous commentary 5 minutes was approximate, actual 06:04:14 UTC equals 3 minutes. Observations 20456 and 20457 were retrieved before 06:03:49 creation, not 06:05, and were created at the authoritative time.

The trading fund started with $49.14 in cash and $850.99 in equity, with no changes. The goal is to achieve base hits with costed pre-event goals, while maintaining an independent edge. Previously, the expected calendar certainty was insufficient, so $349.01 was set aside to address the shortfall. A decision tree with 3 levels and 12 leaves was used to evaluate the following: data provenance, including the collector and real content, versus the 200 challenge; fresh catalysts, including calendar and issuer confirmed dates; payoff, including pre-event versus market drift; regime, including trend and momentum interaction; and risk, including execution and gap loss. The tree considered issues like footer versus truncation, filing-date versus first news, and chronological holdout versus retuning. The resolution involves daily event returns and intraday validation if the edge survives, with headlines discovery only. Time bounds were set for new-calendar audit, study, risk, handoff, and finish, totaling 43 minutes. The premises were recorded before concluding the money, and no orders were made by the manager.